An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
Condition: Neuroendocrine Tumors Intervention: Drug: Surufatinib Combined With Temozolomide and S-1 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Brain | Cancer | Cancer & Oncology | China Health | Hospitals | Neurology | Research | Study | Temodar